Picture of Regulus Therapeutics logo

RGLS — Regulus Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Regulus Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

* Regulus Therapeutics Inc  RGLS.OQ  reported a quarterly
adjusted
loss of 21 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -40 cents.  The mean expectation of six analysts
for the quarter was for a loss of 17 cents per share. Wall
Street expected results to range from -19 cents to -13 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Regulus Therapeutics Inc's reported EPS for the quarter
was a
loss of 21 cents​.
    * The company reported a quarterly loss of $14.06 million.
    * Regulus Therapeutics Inc shares had fallen by 3.8% this
quarter and gained 18.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $7.50 
This summary was machine generated from LSEG data November 8 at
02:19 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.17          -0.21          Missed
 Jun. 30 2024      -0.15          -0.17          Missed
 Mar. 31 2024      -0.22          -0.29          Missed
 Dec. 31 2023      -0.39          -0.40          Missed

Recent news on Regulus Therapeutics

See all news